^
    Back
    Association details:
    Biomarker:ALK rearrangement + BRCA2 F2801fs
    Cancer:Lung Adenocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis

    Published date:
    03/23/2022
    Excerpt:
    We report a case of a 27-year-old female nonsmoker diagnosed with ALK-rearranged metastatic lung adenocarcinoma….Germline BRCA2 p.F2801fs was also identified….Afterward lorlatinib plus olaparib was started and elicited a rapid response within 1 month. The progression-free survival was 6 months as of the latest follow-up, with the best response of partial response. To the best of our knowledge, this case is the first to provide clinical evidence of antitumor activity of olaparib plus ALK TKI in ALK-positive, gBRCA-mutated metastatic NSCLC.
    DOI:
    10.1097/CAD.0000000000001303